Vir Biotechnology, a Phase 2 biotech developing immunologic therapies for infectious diseases, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.
The San Francisco, CA-based company was founded in 2016 and booked $12 million in revenue for the 12 months ended June 30, 2019. It plans to list on the Nasdaq under the symbol VIR. Goldman Sachs, J.P. Morgan, Cowen and Barclays are the joint bookrunners on the deal. No pricing terms were disclosed.
